



- (51) **International Patent Classification:**
C12N 15/113 (2010.01)
- (21) **International Application Number:**
PCT/US2013/061320
- (22) **International Filing Date:**
24 September 2013 (24.09.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/705,335 25 September 2012 (25.09.2012) US
- (71) **Applicant:** GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors:** LEGER, Andrew; c/o SANOFI U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). WENTWORTH, Bruce; c/o Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). NELSON, Carol A.; 18 Maple Street, Westford, Massachusetts 01996 (US). WEEDEN, Timothy E.; c/o Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). CLAYTON, Nicholas; c/o Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). CHENG, Seng; c/o Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US).
- (74) **Agents:** SZCZEPANIK, Ann Marie et al.; Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** PEPTIDE-LINKED MORPHOLINO ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF MYOTONIC DYSTROPHY

(57) **Abstract:** Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3' untranslated region of the gene encoding dystrophin myotonia-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of myotonic dystrophy type I (DM1).

